Thanks Tattie. had a look at the note. HLA still on track to do well vs prospectus but acquisitions have come through a little slower than the analyst had forecast so adjusted down the Fy19 numbers slightly but left Fy20 alone. price target of approximately $1.30 remained unchanged.
